Biote Corp. shares rise 7.29% intraday as biotech sector growth and innovation drive investor optimism.

Biote Corp. rose 7.29% intraday, with the biotechnology sector entering a dynamic growth phase fueled by advances in gene therapy, AI-assisted drug discovery, and personalized medicine. Global biotech revenue is projected to grow from $1.55 trillion in 2024 to over $4.6 trillion by 2034, reflecting a surge in both investment and innovation. Venture funding is rebounding strongly, with billions pouring into early-stage companies developing transformative therapies. This creates a unique opportunity for investors, as small-cap and emerging biotech firms are often operating under the radar, tackling complex medical challenges with innovative approaches.